Suppr超能文献

终末期肝病模型及肝硬化相关并发症

Model for End-Stage Liver Disease and liver cirrhosis-related complications.

作者信息

Bertot Luis Calzadilla, Gomez Eduardo Vilar, Almeida Linnet Alonso, Soler Enrique Arus, Perez Luis Blanco

机构信息

Department of Hepatology, National Institute of Gastroenterology, Havana, Cuba.

出版信息

Hepatol Int. 2013 Jun;7(2):347-55. doi: 10.1007/s12072-012-9403-2. Epub 2012 Oct 10.

Abstract

The Model for End-Stage Liver Disease (MELD) score has gained wide acceptance for predicting survival in patients undergoing liver transplantation. The strength of this score remains in the mathematical formula derived from a multivariate Cox regression analysis; it is a continuous scale and lacks a ceiling or a floor effect with a wide range of discrimination. It is based on objective, reproducible, and readily available laboratory data and the wide range of samples which have been validated. Liver cirrhosis complications such as ascites, encephalopathy, spontaneous bacterial peritonitis and variceal bleeding were not considered in the MELD score underestimating their direct association with the severity of liver disease. In this regard, several recent studies have shown that clinical manifestations secondary to portal hypertension are good prognostic markers in cirrhotic patients and may add additional useful prognostic information to the current MELD. We review the feasibility of MELD score as a prognostic predictor in patients with liver cirrhosis-related complications.

摘要

终末期肝病模型(MELD)评分在预测肝移植患者的生存率方面已获得广泛认可。该评分的优势在于其数学公式源自多变量Cox回归分析;它是一个连续量表,具有广泛的区分度,不存在上限或下限效应。它基于客观、可重复且易于获取的实验室数据以及经过验证的大量样本。MELD评分未考虑肝硬化并发症,如腹水、肝性脑病、自发性细菌性腹膜炎和静脉曲张出血,低估了它们与肝病严重程度的直接关联。在这方面,最近的几项研究表明,门静脉高压继发的临床表现是肝硬化患者良好的预后标志物,可能会为当前的MELD评分增添额外有用的预后信息。我们回顾了MELD评分作为肝硬化相关并发症患者预后预测指标的可行性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验